[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-363656-105":59,"doc-detail-363656-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","a-fibroblast-activation-protein-degrader-enhances-cisplatin-sensitivity-in-non-small-cell-lung-cancer","A fibroblast activation protein degrader enhances cisplatin sensitivity in non-small cell lung cancer","","Cisplatin’s therapeutic effectiveness against non-small cell lung cancer (NSCLC) is constrained by acquired resistance. This study used a fibroblast activation protein (FAP) degrader (Pomalidomide-PEG2-FAP2286: FAP-D) to increase cisplatin sensitivity in NSCLC. Cell viability, migration, and apoptosis were evaluated in NCI-H1299 and NCI-H460 cells and in heterogeneous tumor models in mice. FAP-D promoted FAP and CD26-related molecular changes, reduced cisplatin IC50, enhanced tumor suppression, and strengthened apoptotic features in cells and tumors.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/a-fibroblast-activation-protein-degrader-enhances-cisplatin-sensitivity-in-non-small-cell-lung-cancer/363656/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/a-fibroblast-activation-protein-degrader-enhances-cisplatin-sensitivity-in-non-small-cell-lung-cancer/363656.png","ImageObject",300,407,{"name":92,"@type":93},"Ben ","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-13","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",13,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"What problem does the study address regarding cisplatin in NSCLC?","Question",{"text":113,"@type":114},"Cisplatin’s clinical utility is limited by drug resistance in NSCLC. The study aims to enhance cisplatin sensitivity to overcome this limitation.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"How does the study test the effect of the FAP degrader?",{"text":118,"@type":114},"The research assesses viability of NCI-H1299 and NCI-H460 cells, migration via wound-healing assays, and apoptotic features in tumors using hema toxylin-eosin staining. Tumor growth is also evaluated in mice.",{"name":120,"@type":111,"acceptedAnswer":121},"What key molecular effects are reported for FAP-D?",{"text":122,"@type":114},"FAP-D degrades FAP in a time- and concentration-dependent manner. The study also examines apoptosis markers such as caspase-3 and cleaved caspase-3, and evaluates related protein changes including CD26.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},363656,1790210641,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":34,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},2336478951081,"https://ap-avatar.wpscdn.com/davatar_276721f389ce27ea32af1340a28f341c","ONCOLOGY REPORTS 56: 145, 2026  \nA fibroblast activation protein degrader enhances cisplatinsensitivity in non‑small cell lung cancer  \nYONG ZHOU 1 , RANHUALI 1 , XIAOBO CHEN 1 , CHENG ZHANG 1 , YANAN BAO 1 , YUE CUI 1 , XINGHE TONG 1 , TING XIA 1 , XUDONG YANG 1 , JIQING YANG2 and XIAOCHUAN YIN 1  \n1Department of Thoracic Surgery, First Affiliated Hospital of Kunming Medical University, Kunming, Yunnan 650032, P.R. China; 2Department of Obstetrics, First Affiliated Hospital of Kunming Medical University, Kunming, Yunnan 650032, P.R. China  \nReceived November 26, 2025; Accepted May 29, 2026  \nDOI: 10. 3892/or.2026.9150  \nAbstract. The therapeutic effect of cisplatin against non‑small cell lung cancer (NSCLC), the most common lung cancer, is limited by resistance. In the present study, a fibroblast activa‑ tion protein (FAP) degrader (Pomalidomide‑PEG2‑FAP2286: FAP‑D) was utilized to enhance cisplatin sensitivity in NSCLC. The study specifically assessed the viabilities of NCI‑H1299 and NCI‑H460 cells (human NSCLC cell lines) and the growth of heterogeneous tumors in mice. The binding between FAP‑D and FAP was studied by molecular docking. The ability of FAP‑D to induce FAP and CD26 degradation was examined by western blotting, as was caspase‑3 and cleaved caspase‑3 expression. The viabilities of H1299 and H460 cells were analyzed using a Cell Counting Kit‑8 assay (CCK‑8). Cell migration rates were studied via wound‑healing assays. Apoptotic features were confirmed in tumors by hema‑ toxylin‑eosin staining assay. FAP was degraded by FAP‑D ina time‑ and concentration‑dependent manner, whereas CD26 protein expression was not altered by FAP‑D. FAP‑D exhib‑ ited favorable biocompatibility. The half‑maximal inhibitory concentration (IC50) of cisplatin was reduced by co‑treatment with FAP‑D, which could be attributable to the inhibition of cell migration by FAP‑D. Heterogeneous tumor growth was also strongly suppressed by cisplatin + FAP‑D. The apoptotic features of H1299/H460 cells and tumors were enhanced by cisplatin + FAP‑D treatment. In conclusion, the study demon‑ strated that FAP‑D can enhance the cisplatin sensitivity of H1299 cells and NSCLC tumors. The present findings shed new light into promising treatment strategies and demon‑ strated the potential clinical utility of cisplatin + FAP‑D for NSCLC treatment.  \nCorrespondence to: Professor Xiaochuan Yin, Department of Thoracic Surgery, First Affiliated Hospital of Kunming Medical University, 295 Xichang Road, Kunming, Yunnan 650032, P.R. China  \nE‑mail: [yxc9701@163.com](yxc9701@163.com)  \nKey words: non‑small cell lung cancer, cisplatin, fibroblast activation protein, apoptosis  \nIntroduction  \nNon‑small cell lung cancer (NSCLC) accounts for ~85% of all lung cancers (1,2) . NSCLC is often classified into three main histological subtypes: Adenocarcinoma, squamous cell carcinoma and large cell carcinoma (1) . Although smoking is the main risk factor for NSCLC (3), the incidence of NSCLCis also increasing among non‑smokers who are exposure to tobacco (1) . The standard treatment of NSCLC consists of surgery, chemotherapy, radiation therapy, targeted therapy and immunotherapy (4) . Chemotherapy is the standard treat‑ ment modality for early‑stage NSCLC (4). Similarly, favorable curative effects have been achieved through advances in radio‑ therapy techniques (5) . Moreover, the most common targeted therapeutic strategy is vascular endothelial growth factor (6‑8) or epidermal growth factor receptor inhibition (9,10). However, issues such as drug resistance, systemic toxicity and high costs remain major obstacles for the adoption of these strategies.  \nFor decades, platinum‑based chemotherapeutics have dominated the treatment of NSCLC (11‑13) . Among them, cisplatin has become the most commonly used first‑line drug because of its excellent efficacy (14) . Unfortunately, chemo‑ resistance often develops during treatment, which seriously limits the clinical utility of cisplatin (1","cbCaiv5yc8pQEVtQ","https://ap.wps.com/l/cbCaiv5yc8pQEVtQ","pdf",2013155,"English","# Abstract\n# Introduction\n# Materials and methods","[{\"question\":\"What problem does the study address regarding cisplatin in NSCLC?\",\"answer\":\"Cisplatin’s clinical utility is limited by drug resistance in NSCLC. The study aims to enhance cisplatin sensitivity to overcome this limitation.\"},{\"question\":\"How does the study test the effect of the FAP degrader?\",\"answer\":\"The research assesses viability of NCI-H1299 and NCI-H460 cells, migration via wound-healing assays, and apoptotic features in tumors using hema toxylin-eosin staining. Tumor growth is also evaluated in mice.\"},{\"question\":\"What key molecular effects are reported for FAP-D?\",\"answer\":\"FAP-D degrades FAP in a time- and concentration-dependent manner. The study also examines apoptosis markers such as caspase-3 and cleaved caspase-3, and evaluates related protein changes including CD26.\"}]","A fibroblast activation protein degrader enhances cisplatin sensitivity in non-small cell lung cancer | PDF",1790152524,18,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/8de2a842a60bf65c0926ebfd086cb998.webp",983,1357,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/e78af1a3bea02de0ffd8406a5dd53895.webp",982,1356,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/8f17e79bd8c93bbf37e96ea642d04ed2.webp",981,1354,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/1edc276de7dc23ef68696ec4cd6d65a0.webp",980,1353]